Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
about
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinomaRecent advances in hepatocellular carcinoma therapy.Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies.Targeting the tumor stroma in hepatocellular carcinoma.Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.Molecular classification of hepatocellular carcinoma: potential therapeutic implications.Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.Cancer Immunotherapy Targeted Glypican-3 or Neoantigens.In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment.Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.Proteoglycans-Biomarkers and Targets in Cancer Therapy.I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma.Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma
P2860
Q26772321-A28DE053-98F3-49ED-B158-42561A4A0DE4Q30236010-0E64EC13-6D9C-4063-9EAD-240D621796ADQ36870030-9913A926-0E51-4265-A46B-BC20812777D4Q38366586-5AB1771C-F55A-4AA2-A0C1-65DBE1261A07Q38554626-B28DA0D5-09E8-444C-8895-09AF2A42B5C8Q39000945-E539A7BA-0544-4CB8-AB37-34D1A877AD1BQ39378285-D0F4796B-B766-42A3-A616-6845967C2F01Q40069479-17636F51-81C8-487F-8C6D-D1B6E36A6B9EQ43059019-7EFAC67E-48EF-45A2-B825-38AA7FE2EC2DQ45857417-9E1F0BA1-3D47-4A7E-BDA7-2E710838FB1FQ47704854-C79D70A2-CED4-4A21-8B22-1D147EF7A957Q47760070-272E823B-026F-4923-83E9-BEC6B7D29F30Q48304356-BC3A5ADF-E66E-49A6-826A-B77485D665B5Q50022186-F4EC4356-3B29-46D6-9DCD-31198AF3D15DQ51732657-D213784E-8F9C-4D3D-9A02-DD53C2F46097Q52672750-5A644C2B-1552-4A31-810E-4C6856D5708BQ58556622-A875CBBA-691A-406F-96BC-3665ECFF6091
P2860
Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Japanese phase I study of GC33 ...... nced hepatocellular carcinoma.
@ast
Japanese phase I study of GC33 ...... nced hepatocellular carcinoma.
@en
type
label
Japanese phase I study of GC33 ...... nced hepatocellular carcinoma.
@ast
Japanese phase I study of GC33 ...... nced hepatocellular carcinoma.
@en
prefLabel
Japanese phase I study of GC33 ...... nced hepatocellular carcinoma.
@ast
Japanese phase I study of GC33 ...... nced hepatocellular carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Japanese phase I study of GC33 ...... nced hepatocellular carcinoma.
@en
P2093
Chigusa Morizane
Ikue Suzuki
Junji Furuse
Masafumi Ikeda
Satoshi Kobayashi
Shinichi Ohkawa
Shuichi Mitsunaga
Shunsuke Yamamoto
Takuji Okusaka
P2860
P304
P356
10.1111/CAS.12368
P577
2014-03-25T00:00:00Z